Marco Massari to Hospitalization
This is a "connection" page, showing publications Marco Massari has written about Hospitalization.
Connection Strength
0.098
-
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology (Oxford). 2021 10 09; 60(SI):SI25-SI36.
Score: 0.026
-
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Drug Saf. 2020 12; 43(12):1297-1308.
Score: 0.024
-
Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study. Ann Rheum Dis. 2020 07; 79(7):986-988.
Score: 0.023
-
Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021. Euro Surveill. 2021 Jun; 26(25).
Score: 0.006
-
The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. PLoS One. 2021; 16(5):e0251768.
Score: 0.006
-
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
Score: 0.006
-
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021 01 01; 181(1):24-31.
Score: 0.006